Tempus AI Inc

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive.

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers persona.

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

Advanced Micro Devices

DraftKings

Cathie Wood bought shares of AMD, DraftKings, and Tempus AI on Tuesday. AMD is growing its data center and AI chips business, but it's struggling badly in other segments.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

BioNTech SE

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in support of BioNTech's next-generation oncology pipeline. Under this.

Tempus Announces Real World Data Collaboration with BioNTech

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, NY. Tempus Founder and CEO, Eric Lefkofsky, will speak in a fireside discussion at the conference on Wednesday, September 4, 2024 at 8:30 a.m. ET. About Tempus Tempus is a technology company advancing precision medicine.

Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Delcath Systems

In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted on uranium development, oil & gas, and clean energy companies. Healthcare-related stocks are in focus as well, with a couple of biotech picks, a skilled nursing facility operator, and a healthcare technology company included.

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.

Biotech Stock Soars 60% in 2024: Cathie Wood's Bold Investment

The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.

Why Tempus AI Stock Skyrocketed Nearly 22% Today

Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.

Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'

Cathie Wood, a prominent advocate for innovative technologies, is making a bold bet on artificial intelligence with her latest investment in Tempus AI Inc. (NASDAQ: TEM).  Known for her strategic focus on transformative technologies, Wood's decision to heavily invest in Tempus reflects her confidence in the company's potential within the burgeoning AI health-tech sector.

Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech?

BERGEN, Norway , Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m study continues to progress as planned.

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Micron Technology

We all know by now that compound interest is hard to visualize. As early as 1256 AD, storytellers began recording the wheat and chessboard problem.

3 Stocks for the AI Age

Tempus AI Inc. TEM, a cutting-edge healthcare diagnostics company, has been on a tear. The stock established a new high of $47.81 on Thursday.

Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment

Personalis Inc

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the recent ASCO meeting. Tempus is serving as exclusive commercial partner for Personalis' ultra-sensitive tumor-informed MRD product for broad patient adoption in breast and lung cancers,.

Personalis and Tempus Announce Expanded Collaboration

Cronos Group

IAMGOLD

Li Auto Inc.

Marathon Digital Holdings

MINISO Group Holding

PACS Group, Inc.

The S&P 500 index touched highs of 5,670 in July. Over the last one month, the index movement has been volatile with a downward bias.

7 Growth Stocks to Buy on Corrections for 3X Returns by 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay has been published in npj Precision Oncology. Titled, “Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities,” the study included analytica.

NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

EHang Holdings Ltd - ADR

First Solar

Ibotta Inc

The recent market correction is a reminder to investors that it's important to remain grounded even during bull markets. By this, I imply having a balanced portfolio and staying away from overvalued stocks.

7 Growth Stocks That Could 7X in the Next 7 Years

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights. Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 Data licensing revenue growth accelerated to 40% year-over-year Expanded into the minimal residual disease (MRD) market with the launch of both t.

Tempus Reports Second Quarter 2024 Results

Rapport Therapeutics Inc

Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.

3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns

Medtronic

Moderna

AI healthcare stocks can potentially revolutionize patient care as we know it. The groundbreaking technology is expected to have a pervasive impact on the investment world, with its most profound anticipated transformations in healthcare.

3 AI-Powered Healthcare Stocks Transforming Medicine

Loar Holdings Inc

Viking Holdings Ltd

ZEEKR Intelligent Technology Holding Ltd

The initial public offering (IPO) and the subsequent listing is one of the best times to buy new growth stocks. The markets are still in a phase of understanding the business potential and there is limited analyst coverage.

7 New Growth Stock Listings That Can Be Long-Term Wealth Creators

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guidelines. This program is part of the larger Tempus Next platform, which is designed to identify care gaps and equip clinicians with ac.

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified data cohorts and has since expanded into a broader, strategic alliance. Remix is.

Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics

Stryker

Across industries, companies will need to adopt AI for growth and survival. A PricewaterhouseCoopers indicates that by 2030, AI could contribute up to $15.7 trillion to the global economy.

3 AI-in-Healthcare Stocks to Buy for Outsized Returns

Archer Aviation

Leonardo DRS Inc

MakeMyTrip

In June 2010, Tesla (NASDAQ: TSLA ) was listed with a market valuation of $2.23 billion. Currently, the EV maker commands a market valuation of $785 billion.

News for Tempus AI Inc Stock (TEM)